DiabetesSeriesLive

CME Presentations

Basal Insulin


Presentations

  • CME
    1.0

    Optimizing Basal Insulin Therapy: Evolving Tools and Treatment Designs

    Speakers:Jason Gaglia, MD, Director of Hood Center for the Prevention of Childhood Diabetes
    Alissa Segal, PharmD, RPh, CDE, CDTC, FCCP, Clinical Pharmacist
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education

    Duration: 60 minutes

    Presented on: February 1, 2017

  • CME
    1.0

    Optimizing Basal Insulin Therapy: Implementation, Management, and Overcoming Barriers

    Speakers:Mary Paschal, RN, MS, CDE, Nurse Educator
    Roger Decker
    Jason Gaglia, MD, Director of Hood Center for the Prevention of Childhood Diabetes
    Alissa Segal, PharmD, RPh, CDE, CDTC, FCCP, Clinical Pharmacist
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education

    Duration: 60 minutes

    Presented on: April 5, 2017


Speakers


CME Information

Basal Insulin as a Foundation of Diabetes Treatments: Innovative Approaches

Jointly provided by Primary Care Network and PlatformQ Health Education, LLC

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network (PCN) and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Online Activity Primary Care Network designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Online On-Demand Enduring Material Primary Care Network designates each enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals will be issued a certificate of participation.

Primary Care Network has been awarded Accreditation with Commendation (2013-2019) by the Accreditation Council for Continuing Medical Education (ACCME).

DATE OF RELEASE/EXPIRATION Live Online Activity Session I: Optimizing Basal Insulin Therapy: Evolving Tools and Treatment Designs Wednesday, February 1, 2017 from 11:00AM – 12:00PM ET. Session II: Optimizing Basal Insulin Therapy: Implementation, Management, and Overcoming Barriers Wednesday, April 5, 2017 from 11:00AM – 12:00PM ET.

Enduring Material Session I: The enduring material will be available from February 1, 2017 – October 5, 2017. Session II: The enduring material will be available from April 5, 2017 – October 5, 2017

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Describe the pharmacokinetics and pharmacodynamics of the newer ultra-long basal and follow-on biologic ("biosimilar") insulin formulations and how these differ from older formulations
Determine indications and methods to transition from analog basal insulin to ultra-long basal insulins and follow-on biologic ("biosimilar") basal insulins to help achieve individualized patient treatment goals
Utilize evidence-based, guideline-driven protocols for therapeutic advancement to basal insulin therapy alone or in combination with other treatment modalities to achieve individualized patient goals
Identify potential patient, provider, and health care system barriers to initiation and titration of established and newer basal insulins, and methods to overcome these barriers
 

TARGET AUDIENCE This activity is intended for endocrinologists, primary care clinicians, physician assistants, nurse practitioners, pharmacists, certified diabetes educators and other health care providers who provide frontline glycemic management for type 2 diabetes and related conditions.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.diabetesserieslive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the pre and post-test and activity evaluation. Participants must receive a minimum score of 70% on the post-test in order to receive a certificate.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

STATEMENT OF DISCLOSURE AND INDEPENDENCE It is the policy of Primary Care Network (PCN) to ensure all of its accredited educational activities are planned, developed, and conducted in accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that PCN accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.

PCN's Resolution of Personal COI Policy aims to ensure that all potential conflicts are identified and resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN accredited Continuing Medical Education (CME) activity are considered Planning Committee Members. Planning Committee Members include individuals involved in a CME activity who may develop, edit, review and/or present content. Planning Committee Members are required to disclose to the participants any real or apparent conflict(s) of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Disclosures:
Richard Beaser, MD None
Alissa r. Segal, PharmD, RPh, CDE, CDTC, FCCP Advisory Board: Boehringer–Ingelheim, Lilly
Jason Gaglia, MD, MMSc Consultant: AbbVie, Genentech Inc. Research/Grants:Janssen Pharmaceuticals Inc., Sanofi Genzyme Corporation
Mary Paschal, RN, MS, CDE None
Roger Decker None

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Brian Koffman, MDCM, DCFP, DABFM, MS Ed Primary Care Network CME Content Reviewer Advisory Board & Speaker's Bureau: Ironwood Pharmaceuticals Patient Speaker: Juno Therapeutics
 

The following PCN planner and manager, Jill Hays, hereby state that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, advisory boards or consultants.

CONTACT INFORMATION Accreditation Support: Please contact Primary Care Network at http://www.primarycarenetwork.org/.

Technical Support: For any technical issues or issues with your CME Certificate, contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com